{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:24:42Z","timestamp":1784247882137,"version":"3.55.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>This study investigates current practices and challenges in managing cancer-associated thrombosis (CAT) among Italian oncologists, with the objective of evaluating adherence to guidelines for primary thromboprophylaxis, treatment approaches, and safety considerations. Additionally, it aims to identify areas for potential improvement in clinical decision-making and standardization of CAT management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cross-sectional survey was conducted between February and June 2024 among Italian oncologists, facilitated by the Italian Network for Supportive Care in Oncology (NICSO). The online survey comprised 16 multiple-choice questions that addressed primary thromboprophylaxis practices, thrombosis treatment, and anticoagulation safety concerns.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 75 oncologists, evenly distributed across the Italian territory, participated in the survey. Among them, 48% consistently administered primary thromboprophylaxis, with a higher prevalence observed in cases of pancreatic (64%) and lung cancers (12%). Overall, 61% utilized risk assessment models (RAMs), mainly the Khorana score. Drug preference varied, with 89% favoring low-molecular-weight heparin (LMWH) for thromboprophylaxis. For established thrombosis, 72% preferred LMWH, administering treatment to 52% of patients for 3 to 6 months. Awareness of drug-drug interactions was high (93%), and 83% expressed concerns about bleeding risks, with renal impairment identified as a significant comorbidity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The survey highlights variability in CAT management, with limited use of RAMs and personalized treatment plans. These findings underscore the need for enhanced clinician education and standardized guidelines to optimize CAT management, including strategies to address bleeding risk and improve the safety of anticoagulation therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1579464","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:12:09Z","timestamp":1754453529000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Current practices and challenges in the management of cancer-associated thrombosis: a survey of Italian oncologists"],"prefix":"10.3389","volume":"15","author":[{"given":"Andrea","family":"Antonuzzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ermacora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Lucchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Platania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e072715","DOI":"10.1136\/bmj-2022-072715","article-title":"Prevention of venous thromboembolism in patients with cancer","volume":"381","author":"Guntupalli","year":"2023","journal-title":"BMJ"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006330","article-title":"The incidence of cancer-associated thrombosis is increasing over time","volume":"6","author":"Mahajan","year":"2022","journal-title":"Blood Adv"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"B4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-022-00346-4","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.02.029","article-title":"Cancer-associated thrombosis: Enhanced awareness and pathophysiologic complexity","volume":"21","author":"Falanga","year":"2023","journal-title":"J Thromb Haemost."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.123.000000","article-title":"Updates in the incidence, pathogenesis, and management of cancer and venous thromboembolism","volume":"43","author":"Girardi","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1055\/a-2175-0478","article-title":"Update on thrombosis risk in patients with cancer: focus on novel anticancer immunotherapies","volume":"44","author":"Moik","year":"2024","journal-title":"Hamostaseologie"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103782","article-title":"Venous thromboembolism in cancer and cancer immunotherapy","volume":"178","author":"Kacimi","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6004\/jnccn.2022.7020","article-title":"Update on guidelines for the prevention of cancer-associated thrombosis","volume":"20","author":"Elshoury","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00223-7","article-title":"International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.02705","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02223-4","article-title":"SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)","volume":"22","author":"Mu\u00f1oz Mart\u00edn","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH","volume":"17","author":"Wang","year":"2019","journal-title":"J Thromb Haemost"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18325","article-title":"Unanswered questions in cancer-associated thrombosis","volume":"198","author":"Sanfilippo","year":"2022","journal-title":"Br J Haematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12957-015-0628-2","article-title":"Venous thromboembolism in cancer patients: an underestimated major health problem","volume":"13","author":"Khalil","year":"2015","journal-title":"World J Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000636","article-title":"Real-world data regarding the management of cancer-associated thrombosis","volume":"32","author":"Tsoukalas","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0957","article-title":"Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): a follow-up survey","volume":"25","author":"Kakkar","year":"2020","journal-title":"Oncologist"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.91a.ccc037","article-title":"Management of venous thromboembolism in patients with active cancer","volume":"91","author":"Dave","year":"2024","journal-title":"Cleve Clin J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07156-9","article-title":"Anticoagulation and bleeding in the cancer patient","volume":"30","author":"Escobar","year":"2022","journal-title":"Support Care Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14111159","article-title":"Venous thromboembolism prophylaxis in gynecologic oncology: A MITO-MaNGO survey","volume":"14","author":"Mongelli","year":"2024","journal-title":"Diagnostics"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0301","article-title":"Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study","volume":"22","author":"Cella","year":"2017","journal-title":"Oncologist"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100866","article-title":"Venous thromboembolism prevention program implementation in a community oncology practice: a cohort study","volume":"38","author":"Ades","year":"2024","journal-title":"Lancet Reg Health Am"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e007338","DOI":"10.1161\/JAHA.117.007338","article-title":"Evidence gaps in the era of non\u2013vitamin K oral anticoagulants","volume":"7","author":"Aronis","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active Malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915103","article-title":"et al Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12185955","article-title":"Management of patients treated with direct oral anticoagulants in clinical practice and challenging scenarios","volume":"12","author":"Luc\u00e0","year":"2023","journal-title":"J Clin Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1177\/03008916231167021","article-title":"Prescribing pattern of anticoagulants in patients with cancer-associated thrombosis: results of a survey among MITO group and AIOM society","volume":"109","author":"Milani","year":"2023","journal-title":"Tumori"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104405","article-title":"Clinical implications of drug\u2013drug interaction in cancer patients treated with innovative oncological treatments","volume":"200","author":"Santamaria","year":"2024","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1579464\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:12:11Z","timestamp":1754453531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1579464\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":32,"alternative-id":["10.3389\/fonc.2025.1579464"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1579464","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"article-number":"1579464"}}